IBRX
Revenue? More like rocket fuel
ImmunityBio came out swinging with its Q1 2026 update, saying net product revenue hit about $44.2 million for the quarter ended March 31. That’s not just growth — that’s the kind of growth that makes biotech investors sit up straight and check whether they’re reading the same slide twice.
The company said product revenue has risen in every quarter since ANKTIVA’s commercial launch, including a 168% jump versus Q1 2025. It also pointed back to full-year 2025 net product revenue of $113.0 million, which gives this quarter a bit more context: this isn’t a one-off pop, it’s a trend line.
Why investors should care
Biotech names can live and die by clinical headlines, but eventually the market asks the annoying adult question: “Cool story — can you sell the thing?” ImmunityBio is starting to answer that with actual dollars instead of just promise.
A few things to keep an eye on:
- ANKTIVA’s commercial momentum is still building quarter after quarter
- Cash and marketable securities totaled $381 million, which gives the company some breathing room
- The stock can still swing on execution, but stronger revenue lowers the “show me” pressure a bit
Big picture
For a biotech, this is the rare update that mixes science with sales in a way investors can actually model. If ANKTIVA keeps climbing and the cash pile holds, ImmunityBio looks less like a science project and more like a business. And that’s the kind of makeover Wall Street usually applauds.